ALXN2350

· Alexion Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALXN2350, covering 2026-03-04 to 2026-03-04. Get the full timeline:

Most recent: Clinical Trial Update: ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy [Phase 1, Phase 2]